Skip to content
10-K

Annual Report

Landos Biopharma, Inc.

0000950170-24-034438

← back to feed
Filed
Mar 21, 2024 12:00 AM ET
Period of report
—
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 15, 2024 3.12M sh
Shares Diluted FY 2023 · Dec 31, 2023 6.28M sh
Shares Diluted restated FY 2023 · Dec 31, 2022 4.03M sh
Stock Repurchased FY 2023 · Dec 31, 2023 $3M
Stock Repurchased FY 2023 · Dec 31, 2022 $0
Capex FY 2023 · Dec 31, 2023 $0
Capex FY 2023 · Dec 31, 2022 $7K
Operating Cash Flow FY 2023 · Dec 31, 2023 −$20.48M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$45.77M
Cash And Equivalents FY 2023 · Dec 31, 2023 $37.5M
Cash And Equivalents FY 2023 · Dec 31, 2022 $36.64M
Stockholders Equity FY 2023 · Dec 31, 2023 $31.79M
Stockholders Equity FY 2023 · Dec 31, 2022 $39.13M
Stockholders Equity FY 2023 · Dec 31, 2021 $76.27M
Current Liabilities FY 2023 · Dec 31, 2023 $6.25M
Current Liabilities FY 2023 · Dec 31, 2022 $6.12M
Total Liabilities FY 2023 · Dec 31, 2023 $6.25M
Total Liabilities FY 2023 · Dec 31, 2022 $6.12M
Current Assets FY 2023 · Dec 31, 2023 $38.04M
Current Assets FY 2023 · Dec 31, 2022 $45.25M
Total Assets FY 2023 · Dec 31, 2023 $38.04M
Total Assets FY 2023 · Dec 31, 2022 $45.25M
Eps Diluted FY 2023 · Dec 31, 2023 −$3.50
Eps Diluted restated FY 2023 · Dec 31, 2022 −$9.76
Eps Basic FY 2023 · Dec 31, 2023 −$3.50
Eps Basic restated FY 2023 · Dec 31, 2022 −$9.76
Sga Expense FY 2023 · Dec 31, 2023 $10.73M
Sga Expense FY 2023 · Dec 31, 2022 $14.88M
Rd Expense FY 2023 · Dec 31, 2023 $12M
Rd Expense FY 2023 · Dec 31, 2022 $25.68M
Net Income FY 2023 · Dec 31, 2023 −$21.94M
Net Income FY 2023 · Dec 31, 2022 −$39.28M
Operating Income FY 2023 · Dec 31, 2023 −$22.73M
Operating Income FY 2023 · Dec 31, 2022 −$40.56M